Cargando…

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors

Detalles Bibliográficos
Autor principal:	Persson, Pontus B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433045/ https://www.ncbi.nlm.nih.gov/pubmed/26005360 http://dx.doi.org/10.2147/CPAA.S80986

Ejemplares similares

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
por: Frost, Charles, et al.
Publicado: (2013)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of GCC‐4401C, a Novel Direct Factor Xa Inhibitor, in Healthy Volunteers
por: Choi, HY, et al.
Publicado: (2016)

Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery
por: Kushnir, Margarita, et al.
Publicado: (2022)

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Erratum to: Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa–PAR2-Mediated Autophagy Suppression
por: Ito, Yusuke, et al.
Publicado: (2021)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
por: Bosch, Floris T.M., et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
por: Rodvold, Keith A, et al.
Publicado: (2019)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
por: Wong, Pancras C., et al.
Publicado: (2011)

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
por: Mendell, Jeanne, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism
por: Wang, Jinhai, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
por: Bruin, Maaike A. C., et al.
Publicado: (2022)

Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors
por: Remko, Milan, et al.
Publicado: (2016)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

Efficacy of Oral Factor Xa Inhibitor for Venous Thromboembolism in a Patient with Antithrombin Deficiency
por: Minami, Kentaro, et al.
Publicado: (2018)

Ischemic stroke and dose adjustment of oral Factor Xa inhibitors in patients with atrial fibrillation
por: Stoll, Svenja, et al.
Publicado: (2020)

Evaluation of oral factor Xa inhibitor‐associated extracranial bleeding reversal with andexanet alfa
por: Nederpelt, Charlie J., et al.
Publicado: (2020)

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
por: Ravandi, F, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2019)

The role of factor Xa inhibitors in venous thromboembolism treatment
por: Cabral, Katherine P, et al.
Publicado: (2015)

Discovery and development of Factor Xa inhibitors (2015–2022)
por: Zheng, Wei, et al.
Publicado: (2023)

Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
por: Groenendaal-van de Meent, Dorien, et al.
Publicado: (2016)

Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
por: Groenendaal-van de Meent, Dorien, et al.
Publicado: (2020)

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
por: Kukulka, Michael, et al.
Publicado: (2016)

A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis
por: Cattrall, J. W. S., et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of an Oral Formulation of Apixaban in Horses After Oral and Intravenous Administration
por: Serpa, Priscila B. S., et al.
Publicado: (2018)

Application of Molecular Modeling to Development of New Factor Xa Inhibitors
por: Sulimov, Vladimir B., et al.
Publicado: (2015)

A Systems Pharmacology Model for Predicting Effects of Factor Xa Inhibitors in Healthy Subjects: Assessment of Pharmacokinetics and Binding Kinetics
por: Zhou, X, et al.
Publicado: (2015)

Coagulation Factor Xa
por: Brown, Mark A., et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor
por: Perera, Vidya, et al.
Publicado: (2022)

Reversing factor Xa inhibitors – clinical utility of andexanet alfa
por: Kaatz, Scott, et al.
Publicado: (2017)

The Development of New Factor Xa Inhibitors Based on Amide Synthesis
por: Tarasov, Dmitry N., et al.
Publicado: (2018)

Less Is More: Microvascular Thrombophylaxis With Factor-Xa Inhibitor Monotherapy
por: Kotha, Vikas S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_crfcuhkjamfgdf8j6b2fn6ahmd